FOR IMMEDIATE RELEASE: Seattle | Feb. 4, 2019: A clinical trial testing two new therapeutic vaccines, one developed by IDRI (Infectious Disease Research Institute) and another by Archivel Farma, was given the green light to proceed at the inaugural meeting of the STriTuVad (In Silico Trial for Tuberculosis) consortium held recently in New Delhi, India.

The consortium is focused on demonstrating how advanced computer modelling and simulation can be used to reduce the costs of clinical trials to test the efficacy of new therapies for tuberculosis. The project is funded by the European Commission through the Horizon 2020 program and by the Department of Biotechnology of the Indian Ministry of Science & Technology. Led by Etna Biotech in Italy, the consortium includes some of the leading researchers in this field, including IDRI; Universita Degli Studi Di Cantania and the University of Bologna in Italy; the University of Sheffield in the United Kingdom, Archivel Farma in Spain; Stichting Tuberculosis Vaccine Initiative I the Netherlands and the All India Institute of Medical Sciences in India.

The inaugural meeting offered the opportunity to outline the objectives of the project, highlighting the importance of international cooperation in addressing health concerns in India which, in turn, could become global challenges. Tuberculosis (TB) is one of the world’s deadliest infectious diseases: one third of the world’s population, mostly in developing countries, is infected with TB. There is now a growing awareness that TB can only be effectively fought by working globally, starting with countries like India, where the infection is endemic.

During the meeting, IDRI’s Chief Scientific Officer Corey Casper, MD, spoke about the design of the clinical trial that will usestrituvad IDRI’s TB vaccine — ID93 + GLA-SE — as adjunctive immunotherapy to multi-drug therapy for TB. “The novelty of this study is that it will determine whether an immunotherapeutic vaccine is helpful in increasing the success of treatment for pulmonary TB in an endemic region, and ultimately could increase the rate of cure, reduce the frequency of drug-resistant TB developing, and potentially shorten the length of what is currently arduous treatment for TB,” said Casper.

The clinical trial will also be used to quantify the predictive accuracy of a new computer model, developed by Prof. Francesco Pappalardo of the University of Catania, which is capable of predicting the individual response of patients with active TB when treated with new therapies. This information will be essential in the future regulatory qualification on these in silico trials methods, which consortium members hope will speed up and reduce the costs for the development of more effective therapies for tuberculosis.

About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.

Contact: Lee Schoentrup | lee.schoentrup@idri.org